Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Gastric cancer is one the most common maligancies and a considerable health problem throughout the world. Multimodal approach, encompassing both radical surgery and perioperative chemotherapy provides the best chance to cure resectable gastric cancer. Data originating from well-conducted randomized trials demonstrate that chemotherapy improves survival in patients with metastatic disease. During the last years, two targeted therapies have been approved in metastatic setting. Based on promising clinical trials results, it is expected for the near future that immunotherapy to be incorporated in the multimodal treatment of gastric cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.21614/chirurgia.113.6.758 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!